Clinical Trial

Endometriosis and Microvascular Dysfunction: Role of Inflammation

Study acronym: Endo3/SA2
Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to better understand the underlying mechanisms associated with elevated cardiovascular disease risk in women with endometriosis, and to measure the effectiveness of emerging endometriosis treatments on outcomes specific to cardiovascular dysfunction. Epidemiologic data demonstrate a clear association between endometriosis, reproductive risk factors, inflammation and cardiovascular (CV) risk. Circulating factors, low-density lipoprotein (LDL) and oxidized LDL (oxLDL), are two of many biomarkers of cardiovascular and inflammatory disease of endometriosis. An important signaling mechanism through which circulating LDL and oxLDL act is the lectin-like oxidized LDL receptor (LOX-1). LOX-1 signal transduction functionally results in pronounced endothelial dysfunction, a hallmark of CV. The investigators hypothesis that one factor mediating the elevated risk of cardiovascular disease in endometriosis is systemic inflammation and activation of LOX-1 receptor mechanisms.
Protocol Amendment History 1 change
notable Primary completion pushed: 2025-12-31 -> 2026-12-31 2026-07-28
Trial Details
NCT Number NCT05069740
Lead Sponsor Penn State University
Conditions Endometriosis
Enrollment 24 participants
Start Date 2022-01-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-27